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Abstract
Purpose The purpose of this study was to assess the overall
burden of pancreatic cancer in Europe, with a focus on sur-
vival time in a real-world setting, and the overall healthy life
lost to the disease.
Methods Real-world data were retrieved from peer-reviewed,
observational studies identified by an electronic search. We
performed two de novo analyses: a proportional shortfall anal-
ysis to quantify the proportion of healthy life lost to pancreatic
cancer and an estimation of the aggregate life-years lost annu-
ally in Europe.
Results Ninety-one studies were included. The median, age-
standardised incidence of pancreatic cancer per 100,000 was
7.6 in men and 4.9 in women. Overall median survival from
diagnosis was 4.6 months; median survival was 2.8–
5.7 months in patients with metastatic disease. The propor-
tional shortfall analysis showed that pancreatic cancer results
in a 98 % loss of healthy life, with a life expectancy at diag-
nosis of 4.6 months compared to 15.1 years for an age-
matched healthy population. Annually, 610,000–915,000
quality-adjusted life-years (QALYs) are lost to pancreatic can-
cer in Europe. Patients had significantly lower scores on val-
idated health-related quality of life instruments versus popu-
lation norms.
Conclusions To the best of our knowledge, this is the first
study to systematically review real-world overall survival
and patient outcomes of pancreatic cancer patients in Europe
outside the context of clinical trials. Our findings confirm the
poor prognosis and short survival reported by national studies.
Pancreatic cancer is a substantial burden in Europe, with near-
ly a million aggregate life-years lost annually and almost com-
plete loss of healthy life in affected individuals.
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Introduction
Pancreatic cancer is among the most deadly malignancies;
despite being responsible for only 3 % of all new cancer di-
agnoses, it was the fourth most common cause of cancer death
in the United States in 2013 [1] and is expected to be the
second most common cause by 2030 [2]. The reported inci-
dence is highest in developed countries, which likely reflect
more accurate diagnosis, with Europe bearing a significant
part of the burden [3]. In 2008, Europe carried one quarter
of the global burden, despite comprising only one ninth of
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the world population [4]. Accurate data on cancer incidence
and mortality in Europe are therefore crucial in assessing the
burden of disease, the effectiveness of control programmes
and for budgeting and planning at national and regional levels.
Current treatment options for pancreatic cancer are
limited, with surgical resection presently the only poten-
tially curative treatment option [5, 6]. However, owing
to the frequently advanced stage at diagnosis, 80–90 %
of patients have unresectable tumours [5], and long-term
survival after surgical resection is poor [6]. New treat-
ments have recently been approved and are expected:
chemotherapy has demonstrated a favourable impact in
overall survival when prescribed after surgery with cu-
rative intent [7]; gemcitabine and erlotinib are approved
in the USA and Europe for use in metastatic disease;
and nab-paclitaxel has recently been approved in
Europe and the USA to treat metastatic disease. In order
to improve long-term outcomes for pancreatic cancer
patients, it is imperative that patients have access to
the range of new treatment options. Key stakeholders
in this process are healthcare payers. In order to support
the introduction of these treatments, real-world survival
times provide a meaningful context in which to evaluate
improvements in patient outcomes. Survival times are
an important way of capturing the unmet medical needs
of a patient as they allow the calculation of shortfall.
They also allow us to capture the unmet medical needs
at a societal level through the number of aggregate life-
years lost to the disease [8].
To our knowledge, no published studies have systematical-
ly reviewed the real-world survival time in Europe outside
context of clinical trials. The objective of the systematic re-
viewwas therefore to perform a systematic, macroscopic anal-
ysis of the burden of pancreatic cancer in Europe on individ-
uals and health systems, to evaluate the direct and indirect
costs of the disease, and to assess the extent of the unmet
needs.
Methods
The research comprised two phases: a systematic review of
published data and related de novo analyses.
Systematic Review Methods
Studies were identified through a search of MEDLINE and
other major bibliographic databases for studies published in
English through 5th April 2013. Additional information was
obtained from searches of conference proceedings for the
2 years preceding April 2013 and targeted searches of health
economic databases. Only epidemiological or non-
interventional studies were selected for data extraction; eligi-
bility and exclusion criteria are shown in Table 1 (see online
resource for details of databases and search terms). Grey liter-
ature, such as unpublished reports from disease registry
websites, was not included. Studies based on the same dataset
were systematically excluded in order to avoid multiple
reporting of the same data.
Two independent reviewers performed the review and full-
text extraction; any differences were resolved by a third re-
viewer. No quantitative syntheses, e.g. meta-analysis, were
performed. Overall medians of median values reported in in-
dividual studies were calculated as summary measures.
De Novo Analysis: Proportional Shortfall
Proportional shortfall (PS) was calculated as follows [9]:
PS ¼ disease related QALY loss
remaining QALY expectation in absence of the disease
Quality-adjusted life-year (QALY) expectation or ‘health
life’ in the absence of pancreatic cancer was calculated by
multiplying the mean life expectancy of patients aged 71 in
EU 28 countries (15.1 years) [10], by the mean health-related
Table 1 Study inclusion and exclusion criteria
Study types eligible for inclusion Study types that were excluded
• Observational/uncontrolled cohort studies (prospective/retrospective
longitudinal studies, cross-sectional studies)
• Studies with both observational and interventional phases
• Database studies, registries
• Studies with no available abstract
• Interventional trials (parallel and crossover design, double-blind,
single-blind, open label) with no observational phases
• Phase I, II, III or IV studies
• Case reports or case series
• Case–control studies
• In vitro studies/genetic studies/molecular epidemiology studies
• Imaging/diagnostic studies; studies assessing techniques
• Classification schemes (e.g. studies assessing staging schemes)
• Studies focusing on pathophysiology or prevention
• Systematic reviews
• Editorials, letters, comments, non-systematic review articles
• Guidelines
• Policy/prioritisation papers/research recommendations
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quality of life (HRQoL) of this age group (0.78=weighted
health state index for the UK population aged 65–74) [11].
Pancreatic cancer-related QALYs were calculated by multi-
plying the median patient survival in months, derived from
the current systematic review, by the EQ-5D utility obtained
from a German study of 45 pancreatic cancer patients (mean
EQ-5D utility 0.65; mean age 64 years) [12].
De Novo Analysis: Aggregate Life-Years Lost
Aggregate life-years lost to pancreatic cancer was calculated
from the difference in survival between pancreatic cancer pa-
tients and the general population multiplied by the annual
number of incident pancreatic cancer cases across Europe ob-
tained from three different sources: GLOBOCAN incident
cases derived from crude incidence estimates (79,331 cases)
[13]; crude incidence rates from the current systematic review
multiplied by the EU 28 population of 507.2 million [14] (62,
203 cases); and age-adjusted (European standard) rates de-
rived from the current systematic review multiplied by the
EU 28 population (52,872 cases). QALYs lost per person (cal-
culated as per the PS analysis) were multiplied by the incident
cases of pancreatic cancer in Europe to derive the aggregate
QALYs lost. Analyses were performed for all patients with
pancreatic cancer and metastatic patients (based on an estimat-
ed 62.5 % patients having Stage IV disease as a proportion of
all patients in Stages I to IV [15]).
Results
Search and Selection of Studies
The search of the electronic databases retrieved 2027 citations;
7 additional studies were identified in conference abstracts
and economic databases (Fig. 1). After review, 91 studies
met the inclusion criteria (study characteristics are described
in online resources).
Studies contained data from all regions of Europe, with
some publications reporting data from several different
counties and regions. The number of studies reporting data
from the different countries is shown in Fig. 2. The
Scandinavian countries, the UK and Italy were the most rep-
resented and the Baltic and Balkan states the least represented.
Year of publication ranged from 1973 to 2013, with the ma-
jority (72 %) published in the last 10 years. Study durations
ranged from <1 year to >60 years (see Table S1). In studies of
patient registries, the number of patients with pancreatic can-
cer (where reported) ranged from 48 (regional registry) to 69,
304 (WHO international registry) with 35 % containing >20,
000 patients. Registries were not exclusively pancreatic can-
cer specific; individual registries also contained data for up to
1.76 million non-pancreatic cancer patients. In cohort, cross-
sectional and other studies, the number of patients with pan-
creatic cancer ranged from 17 to 2196, with 88 % of studies
including <500 patients. Where reported, the mean age of
study subjects ranged from 50 to 75 years (median range 57
to 74 years). Six of the studies reported economic data and
five reported data on HRQoL.
Incidence of Pancreatic Cancer
Seventeen publications reported age-standardised incidence
data from 37 study populations in 24 countries [16–32]. In
the majority of populations (33/37), incidence rates were re-
ported as age-standardised based on the World Standard
Population (WSP) [16–28]; four studies reported age-
standardised data based on the European Standard
Population (ESP) [29–32], and five studies reported crude
incidence rates [33–35, 28, 36].Median annual incidence rates
are shown in Table 2. Overall median annual incidence rates
were higher in men than women for all age-adjustment
standards.
Fig. 1 PRISMA flow diagram of
the systematic review study
selection process
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Median Survival
Median survival from diagnosis was reported in 12 studies
[26, 37, 38, 33, 34, 18, 39–44], mainly from Nordic countries
(8/12 studies), and ranged from 1 to 6.1 months, with an
overall median of 4.6 (Fig. 3). The two largest studies (in
Norwegian and Swedish populations of 21,663 and 16,758
patients, respectively) both reported a median survival of
3 months [33, 18]. When reported, stage at diagnosis was
generally advanced, with half the studies reporting >40 % of
patients with metastatic disease [26, 34, 39–41, 43]. In gener-
al, median survival was shorter in older populations (1 to
3.2 months; median age 70–76 years) versus younger ones
(5 to 6.1 months; median ages 62–67 years).
Survival Rates at 1 and 5 Years
Combined survival data for both sexes were available from 32
studies or sub-studies reported in 17 publications [45–49, 44,
34, 50, 37, 38, 33, 51–54, 29, 43] (Figure S1 in the online
resource). Combined 1-year survival rates ranged from 10 to
23 %. The largest study in a population of 30,025 Dutch
patients [49] reported a 1-year survival rate of 16 %. The
overall median 1-year survival across studies was 15 %.
Combined 5-year survival rates ranged from 0.5 % in
Sweden [37] to 9 % in Slovenian [46] and German popula-
tions [47]. The two largest studies reported 5-year survival
rates of 3 and 5 % [49, 48]. Overall median 5-year survival
across studies was 3 %.
Survival Rates at 1 and 5 Years by Sex
Survival rates at 1 and 5 years by sex were reported in 33
studies or sub-studies in nine publications [53, 36, 38, 42,
55, 18, 56, 31, 48]. Overall median values across studies were
15 % in women and 14 % in men at 1-year and 4 % in both








1 - 5 studies
6 - 10 studies
11 - 15 studies
16 - 20 studies
>20 studies
Fig. 2 Geographic distribution of the selected epidemiological studies
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Survival by Disease Stage
The effect of disease stage (irrespective of intervention) on
median survival from diagnosis was reported by three studies
[41, 43, 39]. As expected, survival rates decreased with ad-
vancing stage. In a Dutch population between 1985 and 2001,
survival rates at 1 year were 40, 30, 35, 25 and 5 % for stages
I, II, III, IVa and IVb, respectively [15]. In a Finnish popula-
tion between 1947 and 1980, 1-year survival rates were 53,
19, 17 and 12% for stages I, II, III and IV, respectively [53]. In
the aforementioned Dutch population, survival at 5 years was
15, 1, 5 and 1 % among patients with stages I, II, III and IV
disease, respectively [15].
Median Survival by Intervention
Five studies reported survival from diagnosis by intervention;
four were in Scandinavian populations [44, 37, 38, 33] and
one in an Italian population [34]. Patients who underwent
resection or radical surgery consistently showed the longest
median survival, ranging from 11 to 25.7 months. In patients
who underwent chemotherapy, radiotherapy, palliative sur-
gery or exploratory laparotomy, median survival ranged from
2 to 8.1 months. Patients who received no surgery or best
supportive care had a median survival of 1.1 month
(Figure S2 in the online resource).
The shorter survival among patients treated with chemo-
therapy, radiotherapy, palliative surgery or exploratory
laparotomy reflects the more advanced stage of disease in
these patients (54 % of patients treated with chemotherapy/
radiotherapy and 52 % with best supportive care had stage IV
disease, versus 3 % of patients receiving resective/radical
surgery).
Mortality
Sixteen studies reported age-standardised mortality rates,
based on the WSP [57–66, 17, 21, 67] or ESP [68, 17,
31], and five studies reported crude rates [52, 63, 69,
64, 21]. Mortality data were derived almost solely from
the World Health Organisation (WHO) and EUROCARE
registries. In pan-European registry studies, median rates
were from 5.0 per 100,000 in women and 7.7 per 100,
000 in men, with similar rates across the EU5, Nordics
and Eastern European regions. The highest median rates
in men and women were recorded in Eastern Europe
and the Nordic regions, respectively (Table 4).
Age-standardisedmortality rates based on the ESP inwom-
en and men ranged from 7.4 to 9.7 per 100,000, respectively,
in England/Wales to 11.8 and 15.3, respectively, in the
Netherlands [68, 30, 31]. Crude mortality rates per 100,000
ranged from 11.2 [52] to 16.7 [63] in women and from 12.5
[69] to 16.5 [63, 64] in men.
Data were not evenly distributed over time, with the ma-
jority coming from the period 2000 to 2006. Women had
Table 2 Median annual
incidence rates of pancreatic
cancer in Europe by sex: age-
standardised and crude rates
Annual incidence rate per 100,000: median (range)
Women Men Totala
Age-standardised: World (33 studies) 4.9 (3.2–9.8) 7.6 (5–14.1) 6.29
Age-standardised: Europe (4 studies) 9.2 (7.7–11.2) 11.8 (10–16.5) 10.43
Crude: (5 studies) 11.5 (6.1–14.7) 12.2 (8–15.4) 12.27
a Calculated with weighting based on 51 or 52 % male (as per study, or assumed if not reported)
Fig 3 Median survival from diagnosis in months bymedian age. Data represents median survival of the overall study population ordered bymidpoint of
study period
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lower mortality rates than men at all time periods where data
were collected.
HRQoL
Five studies reported HRQoL data [40, 70, 12, 71, 72]. In
general, patients with pancreatic cancer had significantly low-
er scores on validated European Organisation for Research
and Treatment of Cancer (EORTC) HRQoL scales than the
general population, with the most significant symptoms being
pain, appetite loss and insomnia. Patients with pancreatic can-
cer experienced depression and anxiety; cognitive, social and
physical function tended to be high, while global health was
low (Fig. 4).
Three studies evaluated depression and anxiety in patients
with advanced disease [70, 40, 12]. In a Swedish population,
42 % of patients reported moderate or severe anxiety and
depression. In a German study, the number of patients
experiencing anxiety/depression was around 10-fold higher
than population norms [12].
Economic Burden
Three studies reported direct costs [39, 73, 74] and two indi-
rect costs [73, 74] associated with pancreatic cancer. In
Sweden, the mean monthly total cost of care from 2005 to
2007 was just over €6500 per month [74], corresponding to
€16,066 over the residual lifetime. In Germany, total costs
were considerably higher at €31,375 over the residual lifetime
or €48,900 per year [73]. Data on the relative contribution of
indirect versus direct costs to the overall cost were not consis-
tent between countries. In Sweden, indirect costs accounted
for a greater proportion of overall costs than direct costs (€83,
109 versus 16,066, respectively) [74], whereas the opposite
was reported in Germany (€28,164 versus 3210) [73].
Five studies reported direct cost data [75, 39, 73, 34, 74].
Hospitalisation accounted for the major component of direct
costs per residual lifetime (€7981–16,264), followed by inter-
ventions (radiology, surgery and chemotherapy; €1575–9761)
and chemotherapy alone (€1423–3569).
Two studies reported indirect costs [73, 74]. In Germany,
24 % of diagnosed patients were actively employed, resulting
in a mean productivity loss of €2972 [73]. In Sweden in 2009,
indirect costs were slightly higher for male versus female pa-
tients aged ≤64 years, with mean short-term productivity loss
of €87,205 for men and €49,895 for women; mean productiv-
ity loss per patient due to mortality was €238,843 in men and
€220,543 in women [74].
De Novo Analysis of Proportional Shortfall
Mean age for diagnosis of pancreatic cancer was 71 years. In
Europe, the general population aged 71 can expect an addi-
tional 11.78 years of healthy life, compared with only
0.25 years for patients with pancreatic cancer (0.38 years of
life expectancy multiplied by 0.65 [12]). This corresponds to
an absolute shortfall of 11.53 QALYs, and a proportional
shortfall of 0.98 (11.53/11.78), indicating a 98 % loss of ex-
pected healthy life (Table 5).
De Novo Analysis of Aggregate Life-Years Lost
At 71 years of age, the survival difference (not adjusted by
QoL) between a patient with pancreatic cancer and the general
population is 14.7 years of life per patient (Table 5). Using
GLOBOCAN data on the number of incident pancreatic can-
cer cases [76], this equates to over 1 million life-years lost
across Europe (Table 6) or at least 778,000 life-years lost
using the incidence estimates obtained in the present review.
Discussion
The clinical studies identified represented all regions of
Europe, although the North of Europe, in particular
Scandinavian countries, represented almost half studies.
Survival times in pancreatic cancer are very short; this is partly
Table 3 Survival at 1 and 5 years
from diagnosis 33 studies Survival (%): median (range)
Women Men
1 year 15 (9 [Denmark]–29 [Malta]) 14 (9 [Malta]–22 [Sweden and Finland])
5 years 4 (1.3 [Slovenia]–7.5 [Czech Rep.) 4 (0 [Switzerland]–7 [Estonia])




Annual mortality rate per 100,000:
median (range)
Women Men
Pan-European 5.0 (4.7–5.4) 7.7 (7.2–8)
EU5 4.9 (2.9–5.8) 7.4 (5.3–8.5)
Nordic 5.4 (5.2–7.9) 8.2 (6.8–9.9)
Eastern European 4.9 (2.8–7.2) 8.7 (6.3–12.3)
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explained by the lack of effective treatments and the difficul-
ties in diagnosing the disease early. Data from large cohort
studies and national/regional registries showed 1- and 5-year
survival rates of about 15 and 4%, respectively. Our estimated
median survival from diagnosis of 4.6 months is in line with a
median of 3 months reported in a US study of 32,452 adults
with distant metastatic pancreatic cancer [77] and 10 weeks in
a recent Dutch study of 3099 patients with metastatic disease
[78] and reflects the high number of patients with metastatic
disease at diagnosis. The longest median survival from diag-
nosis was reported in patients who underwent resection or
radical surgery. It is likely, however, that these data are skewed
by disease stage, as patients who underwent resection are
more likely to have had earlier stage disease.
We found that age-standardisation methodology had a no-
table influence on the incidence rate, with median rates rang-
ing from approximately 8–16 per 100,000 annually in men,
and 5–15 per 100,000 in women, depending on the method
used. Incidence rate standardised to the WSP gave the lowest
combined incidence (6.29/100,000), which was similar to
those reported by GLOBOCAN (7/100,000) [76], which in-
cludes estimates from all EU countries. The combined crude
incidence rate estimated from five studies was higher at 12.27/
100,000 annually. Crude incidence rates give a picture of the
actual rate in a population. However, incidence (and other
rates) of cancer are strongly age-dependent; therefore, com-
parisons of crude rates between populations may be mislead-
ing if the age composition of the populations differ. Although
age-standardisation facilitates comparisons, standardised rates
can be deceiving if the age structure of the reference popula-
tion is different to that of the real population. Owing to the
substantially lower rates observed with age-adjustment to the
WSP, we used only crude estimates or figures adjusted to ESP
in the de novo analyses.
Mortality rates were higher in men than in women in all the
studies identified; given the similar survival rates between the
sexes, this is most likely driven by the higher incidence in
men. The majority of studies reported mortality rates as age-
standardised based on the WSP; however, similar to the inci-
dence data, this resulted in substantially lower rates than ESP
age-adjusted and crude estimates, making it questionable
whether this standardisation method is appropriate for the
European population. Mortality rates across European regions
and individual countries were comparable to the Europe-wide
figures. However, one study that used data from the WHO
database reported appreciably higher mortality rates in eastern
European accession countries compared with the European
Union [79].
Expectedly, HRQoL scores were significantly lower and
levels of depression and anxiety higher in patients with pan-
creatic cancer compared with population norms, indicating
that there is scope to improve supportive care of patients until
screening or early diagnosis is improved, or treatments that
provide clear survival advantages become available.
Fig. 4 Results of the EORTC QLQ-30 questionnaire from four studies






Life expectancy at age 71 15.1 years 0.38 years
(4.6 months)
14.7 years
Utility (ages 65–74) 0.78 0.65 0.13
QALYs 11.78 (A) 0.25 (B) 11.53 (C)
Proportional shortfall (C)/(A) 0.98
J Gastrointest Canc (2015) 46:201–211 207
A limitation of the current study is the lack of quantitative
analysis, such as meta-analysis, of the epidemiological data.
Nonetheless, we were able to quantify the aggregate number
of life-years and QALYs lost due to pancreatic cancer in
Europe each year. Various methods of incorporating equity
concerns into standard QALY-based economic evaluations
have been implemented, such as considering different incre-
mental cost-effectiveness ratio (ICER) thresholds [80]. The PS
approach that we have used includes an equity-weighting
component that demonstrates the nearly complete loss of
healthy life associated with pancreatic cancer. Recent devel-
opments such as value-based pricing in the UK and policies in
other countries reflect an increasing willingness of decision-
makers to account for such weightings in QALY-related as-
sessments [81, 82]. The estimates of aggregate life-years and
QALYs lost to pancreatic cancer demonstrate the magnitude
of the disease’s impact in Europe and raise the question of how
health systems are managing this burden.
We found few studies that assessed the cost of pancreatic
cancer; in those identified, methodologies varied between
studies. Hospitalisation accounted for the major component
of direct costs, followed by interventions and chemotherapy,
with some variation between countries. This was consistent
with data from a large US study showing that hospitalisations
and cancer-directed procedures accounted for the largest frac-
tion of health care costs [83].
Conclusions
The findings of this systematic review show that the real-
world median survival time of patients with pancreatic cancer
in Europe was less than 5 months and less than 10 % of
patients survived beyond 5 years. Survival at 1 year was
highest in patients with early stage disease who undergo re-
section, highlighting the need for improved early diagnosis.
Our results confirm those of individual pan-European registry
studies and US studies that report similar incidence and
mortality rates for pancreatic cancer, reflecting the poor prog-
nosis. Our analyses demonstrate the considerable burden of
pancreatic cancer in Europe, with almost a million aggregate
life-years lost and an almost complete loss of healthy life in
affected individuals. Quantifying the number of life-years and
QALYs lost provides a method to compare the relative burden
of different cancers in the context of value-based pricing and
to evaluate treatment options in view of the projected increase
in disease burden [2] over the next 15 years.
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